HomeAI · summaries
Storia in 3 fonti
Sanofi to mull riliprubart’s future after stopping late-stage nerve disease study
Sanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the study was unlikely to show sufficient efficacy.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Sanofi stops immune drug trial in latest research setback
The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.
- ·
endpoints.news
Sanofi to mull riliprubart’s future after stopping late-stage nerve disease study
Sanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the study was unlikely to show sufficient efficacy.
- ·
valor.globo.com
Sanofi encerra estudo de fase avançada de medicamento experimental
A farmacêutica francesa declarou que avaliará se dará continuidade a outros estudos em andamento para o fármaco, chamado riliprubart